Teva Pharmaceutical Industries Ltd. / Mylan N.V.

Generic Pharmaceuticals (Multi-Therapeutic)

Disease Overview

The contemplated combination would have merged two of the top three global generic platforms — Teva and Mylan — across cardiovascular, CNS, respiratory (Mylan's EpiPen), women's health, and HIV generics. The generics segment is structurally challenged by U.S. buyer-group consolidation, FDA generic approval acceleration, and price erosion.

Competitive Landscape (Deal That Wasn't)

Teva's April 21, 2015 unsolicited $40B ($82/share, 50/50 cash/stock, 38% premium to early-April price) expression of interest for Mylan would have created an unrivaled generics colossus combining the #1 (Teva) and #2/#3 (Mylan) global platforms. Mylan's board unanimously rejected on April 27, 2015, calling Teva shares 'low-quality' currency, citing 'significant global antitrust risk,' and questioning industrial logic. Mylan simultaneously pursued its own hostile bid for Perrigo as a defensive maneuver. Teva withdrew on July 27, 2015 and pivoted to acquiring Allergan's Actavis Generics for $40.5B — a transaction that ultimately destroyed value but avoided Mylan's poison pill and Dutch stichting defenses. Had Teva-Mylan closed, the combined entity would have dominated against Sandoz (Novartis), Sun Pharma, Aurobindo, and Dr. Reddy's, but FTC and EU divestitures likely would have exceeded the 79 assets Teva ultimately divested in the Actavis deal. The episode is studied as a case where a target's structural defenses (Dutch incorporation, stichting foundation) defeated a financially superior bid.